Menu
Back to Journals » Research Reports in Clinical Cardiology » Volume 4
Resolute Integrity drug eluting stent safety and efficacy for the treatment of coronary artery disease
Authors Burgos J, Farrag S, Mukherjee D
Received 5 December 2012
Accepted for publication 4 January 2013
Published 22 February 2013 Volume 2013:4 Pages 23—37
DOI https://doi.org/10.2147/RRCC.S31012
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Video abstract presented by Debabrata Mukherjee
Views: 2265
Jose D Burgos, Safa Farrag, Debabrata Mukherjee
Department of Internal Medicine, Paul L Foster School of Medicine, Texas Tech University Health Sciences Center, El Paso, TX, USA
Abstract: The need to develop a local antirestenotic mechanism to prevent in-stent thrombosis has driven the development of new generation stents. The Resolute Integrity® stent is a zotarolimus-eluting system with a new BioLinx™ polymer that allows a slower drug elution. Recently available data has shown the clinical efficacy and safety of this stent in randomized and observational studies. The Resolute Integrity stent system has demonstrated noninferiority when compared with other stents and holds the promise to treat more complex coronary lesions.
Keywords: zotarolimus, BioLinx, coronary stenosis, stents, restensosis, stent thrombosis
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.